US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MapLight Therapeutics, Inc.

13.00

-0.7850-5.69%

Post-market: 13.000.00000.00%19:30 EDT

Volume:340.17K

Turnover:4.50M

Market Cap:602.91M

PE:-2.57

High:14.14

Open:13.88

Low:12.80

Close:13.79

52wk High:40.43

52wk Low:9.10

Shares:46.38M

Float Shares:13.40M

Volume Ratio:0.58

T/O Rate:2.54%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.0580

EPS(LYR):-18.5643

ROE:-111.55%

ROA:-67.11%

PB:1.73

PE(LYR):-0.70

Loading ...

Overview Company News Filings

MapLight Therapeutics price target lowered to $24 from $43 at Canaccord

MapLight downgraded to Equal Weight from Overweight at Morgan Stanley

MapLight Therapeutics is Maintained at Buy by HC Wainwright & Co.

U.S. Research Roundup- BioLife Solutions, Gossamer Bio, Intuit

Maplight Therapeutics Inc : Jefferies Cuts Target Price to $25 from $34

THOMSON REUTERS

Analysts Are Bullish on Top NA Stocks: Syensqo SA/NV (SHBBF), MapLight Therapeutics, Inc. (MPLT)

MapLight's Schizophrenia Drug Fails Once-daily Test, Shares Plunge

Maplight Therapeutics Shares Drop 55.7% Premarket After Co Announces Mid-Stage Trial Results for Schizophrenia Drug

THOMSON REUTERS

Top Premarket Decliners

MT Newswires Live

MapLight Therapeutics announces topline results from ZEPHYR trial

MapLight Says Phase 2 Zephyr Trial Shows Ml-007c-ma Cuts PANSS Score in Schizophrenia

Maplight Therapeutics - to Proceed with Additional Registrational Trial and Engage FDA at End-of-Phase 2

THOMSON REUTERS

Maplight Therapeutics Inc - 330/6 Mg Once-Daily (Qd) Dose Did not Achieve Statistical Significance on Primary Endpoint

THOMSON REUTERS

Maplight Therapeutics Announces Positive Topline Results from Phase 2 Zephyr Trial of Ml-007C-Ma in Schizophrenia

THOMSON REUTERS

Maplight Therapeutics - Ml-007C-Ma Well Tolerated with no Serious or Drug-Related Severe Adverse Events

THOMSON REUTERS

Maplight Therapeutics - 210/3 Mg Bid Dose Shows Significant Panss Improvement at Week 5 in Phase 2 Trial

THOMSON REUTERS

MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

MapLight Therapeutics (MPLT) Rally Puts Its CNS Story And Valuation In Focus

Simply Wall St.

MapLight Therapeutics price target raised to $43 from $35 at Canaccord

U.S. Research Roundup-deckers Brands, Rollins, United Rentals

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/MPLT/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MPLT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","market":"US","secType":"STK","nameCN":"MapLight Therapeutics, Inc.","latestPrice":13,"timestamp":1789156800000,"preClose":13.785,"halted":0,"volume":340166,"hourTrading":{"tag":"盘后","latestPrice":13,"preClose":13,"latestTime":"19:30 EDT","volume":3696,"amount":48048,"timestamp":1789169407465,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.05694595574900255,"floatShares":13402700,"shares":46377800,"eps":-5.058,"marketStatus":"Market Closed","change":-0.785,"latestTime":"09-11 16:00:00 EDT","open":13.88,"high":14.14,"low":12.8,"amount":4504010.783916,"amplitude":0.097207,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.058,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1761537600000,"exchange":"NASDAQ","adjPreClose":13.785,"postHourTrading":{"tag":"盘后","latestPrice":13,"preClose":13,"latestTime":"19:30 EDT","volume":3696,"amount":48048,"timestamp":1789169407465,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5809774238085597,"impliedVol":1.0311,"impliedVolPercentile":0.3699},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","floatShares":13402700,"roa":"-67.11%","roe":"-111.55%","lyrEps":-18.564313,"volumeRatio":0.5809774238085597,"shares":46377800,"dividePrice":0,"high":14.14,"amplitude":0.097207,"preClose":13.785,"low":12.8,"week52Low":9.1,"pbRate":"1.73","week52High":40.43,"institutionHeld":0,"latestPrice":13,"eps":-5.058,"divideRate":0,"volume":340166,"delay":0,"ttmEps":-5.058,"open":13.88,"prevYearClose":17.565,"prevWeekClose":13.77,"prevMonthClose":12.97,"prevQuarterClose":35.84,"fiveDayClose":13.14,"twentyDayClose":11.58,"sixtyDayClose":27.16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MPLT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"MPLT","fiscalQuarterEnding":"2026/06","expectedEps":-1.4,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-05-14","symbol":"MPLT","fiscalQuarterEnding":"2026/03","expectedEps":-0.91,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-1.34},{"market":"US","date":"2026-03-26","symbol":"MPLT","fiscalQuarterEnding":"2025/12","expectedEps":-1.05,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"pre","actualEps":-2.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MPLT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MPLT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3571,"buy":0.5,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":14,"updateTime":1786420800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MPLT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MPLT","date":"2026-09-11","current":-2.570186,"percent":0.862385,"low":-9.047313,"twenty":-8.052399,"median":-7.329236,"eighty":-6.1487,"high":-2.251599,"avg":-6.75607,"sd":1.803722,"marketCap":766111286},"quantilePoints":[{"date":"2025-10-31","current":-8.673514,"twenty":-8.310978,"median":-7.61973,"eighty":-7.489746,"marketCap":801692922},{"date":"2025-11-07","current":-7.620605,"twenty":-8.035178,"median":-7.644213,"eighty":-7.545137,"marketCap":704372551},{"date":"2025-11-14","current":-6.742394,"twenty":-7.98511,"median":-7.554503,"eighty":-7.23627,"marketCap":623199506},{"date":"2025-11-21","current":-6.274959,"twenty":-7.73109,"median":-7.394197,"eighty":-6.810384,"marketCap":579994498},{"date":"2025-11-28","current":-6.435493,"twenty":-7.639491,"median":-7.190943,"eighty":-6.54881,"marketCap":594832581},{"date":"2025-12-05","current":-7.783335,"twenty":-7.714027,"median":-7.115398,"eighty":-6.435493,"marketCap":800383679},{"date":"2025-12-12","current":-8.528142,"twenty":-7.986054,"median":-7.394197,"eighty":-6.45249,"marketCap":876974375},{"date":"2025-12-19","current":-8.462361,"twenty":-8.266224,"median":-7.554503,"eighty":-6.54881,"marketCap":870209954},{"date":"2025-12-26","current":-7.689969,"twenty":-8.289163,"median":-7.620605,"eighty":-6.624355,"marketCap":790782566},{"date":"2026-01-02","current":-7.454432,"twenty":-8.20424,"median":-7.61973,"eighty":-6.670627,"marketCap":766561577},{"date":"2026-01-09","current":-7.295285,"twenty":-8.111814,"median":-7.53948,"eighty":-6.75706,"marketCap":750196044},{"date":"2026-01-16","current":-7.84275,"twenty":-8.074467,"median":-7.609335,"eighty":-6.818055,"marketCap":806493478},{"date":"2026-01-23","current":-7.885189,"twenty":-7.999774,"median":-7.554503,"eighty":-6.827382,"marketCap":810857620},{"date":"2026-01-30","current":-7.885189,"twenty":-8.004018,"median":-7.620167,"eighty":-6.893484,"marketCap":810857620},{"date":"2026-02-06","current":-6.662942,"twenty":-7.999774,"median":-7.609335,"eighty":-6.893484,"marketCap":685170325},{"date":"2026-02-13","current":-7.308017,"twenty":-7.988887,"median":-7.547968,"eighty":-7.020967,"marketCap":751505286},{"date":"2026-02-20","current":-7.605091,"twenty":-7.988887,"median":-7.532944,"eighty":-7.096512,"marketCap":782054282},{"date":"2026-02-27","current":-7.392895,"twenty":-7.98511,"median":-7.541432,"eighty":-7.116712,"marketCap":760233571},{"date":"2026-03-06","current":-7.622066,"twenty":-7.966096,"median":-7.547968,"eighty":-7.127226,"marketCap":783799939},{"date":"2026-03-13","current":-8.122848,"twenty":-7.991064,"median":-7.592359,"eighty":-7.180699,"marketCap":835296817},{"date":"2026-03-20","current":-7.422602,"twenty":-8.000623,"median":-7.590237,"eighty":-7.203617,"marketCap":763288470},{"date":"2026-03-27","current":-5.207658,"twenty":-7.991064,"median":-7.583871,"eighty":-7.203617,"marketCap":839224545},{"date":"2026-04-02","current":-5.640953,"twenty":-7.988887,"median":-7.541432,"eighty":-7.116384,"marketCap":909050820},{"date":"2026-04-10","current":-7.964495,"twenty":-7.986054,"median":-7.516065,"eighty":-6.867043,"marketCap":1283494221},{"date":"2026-04-17","current":-7.720766,"twenty":-7.972363,"median":-7.507481,"eighty":-6.969974,"marketCap":1244216941},{"date":"2026-04-24","current":-7.883252,"twenty":-7.986054,"median":-7.516065,"eighty":-7.077626,"marketCap":1270401794},{"date":"2026-05-01","current":-8.966125,"twenty":-8.009111,"median":-7.554503,"eighty":-7.116384,"marketCap":1444908993},{"date":"2026-05-08","current":-8.214962,"twenty":-8.052399,"median":-7.590237,"eighty":-7.121808,"marketCap":1323857628},{"date":"2026-05-15","current":-6.658186,"twenty":-8.072823,"median":-7.605091,"eighty":-7.121808,"marketCap":1328174850},{"date":"2026-05-22","current":-6.655912,"twenty":-8.056678,"median":-7.585993,"eighty":-6.867043,"marketCap":1327721393},{"date":"2026-05-29","current":-6.769572,"twenty":-8.053247,"median":-7.547968,"eighty":-6.753265,"marketCap":1350394231},{"date":"2026-06-05","current":-6.842314,"twenty":-8.050011,"median":-7.507675,"eighty":-6.705014,"marketCap":1364904847},{"date":"2026-06-12","current":-6.899144,"twenty":-8.036085,"median":-7.484139,"eighty":-6.662816,"marketCap":1376241266},{"date":"2026-06-18","current":-6.64,"twenty":-8.014204,"median":-7.474515,"eighty":-6.654094,"marketCap":1324547195},{"date":"2026-06-26","current":-7.265128,"twenty":-8.003169,"median":-7.454432,"eighty":-6.652876,"marketCap":1449247804},{"date":"2026-07-02","current":-8.201684,"twenty":-8.01675,"median":-7.469285,"eighty":-6.653639,"marketCap":1636071990},{"date":"2026-07-10","current":-9.047313,"twenty":-8.054945,"median":-7.484139,"eighty":-6.655912,"marketCap":1804757904},{"date":"2026-07-17","current":-8.460828,"twenty":-8.122848,"median":-7.507675,"eighty":-6.658186,"marketCap":1687766060},{"date":"2026-07-24","current":-8.008463,"twenty":-8.137812,"median":-7.547968,"eighty":-6.662732,"marketCap":1597528165},{"date":"2026-07-31","current":-3.189291,"twenty":-8.129236,"median":-7.516065,"eighty":-6.653448,"marketCap":636199834},{"date":"2026-08-07","current":-3.018802,"twenty":-8.123697,"median":-7.486261,"eighty":-6.561799,"marketCap":602190577},{"date":"2026-08-14","current":-2.692276,"twenty":-8.099082,"median":-7.474515,"eighty":-6.526795,"marketCap":537055294},{"date":"2026-08-21","current":-2.266153,"twenty":-8.09314,"median":-7.454432,"eighty":-6.435493,"marketCap":520823053},{"date":"2026-08-28","current":-3.032366,"twenty":-8.06605,"median":-7.420317,"eighty":-6.349031,"marketCap":696919516},{"date":"2026-09-04","current":-3.177455,"twenty":-8.055812,"median":-7.370362,"eighty":-6.26295,"marketCap":730264947},{"date":"2026-09-11","current":-3.333426,"twenty":-8.052399,"median":-7.329236,"eighty":-6.1487,"marketCap":766111286}],"updateTime":1789270131239},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MPLT\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654500961","title":"MapLight Therapeutics price target lowered to $24 from $43 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2654500961","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654500961?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:20","pubTimestamp":1785237629,"startTime":"0","endTime":"0","summary":"Canaccord lowered the firm’s price target on MapLight Therapeutics (MPLT) to $24 from $43 and keeps a Buy rating on the shares. The firm updated it...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-price-target-lowered-to-24-from-43-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-price-target-lowered-to-24-from-43-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654006677","title":"MapLight downgraded to Equal Weight from Overweight at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2654006677","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654006677?lang=en_us&edition=fundamental","pubTime":"2026-07-28 18:56","pubTimestamp":1785236218,"startTime":"0","endTime":"0","summary":"Morgan Stanley downgraded MapLight Therapeutics (MPLT) to Equal Weight from Overweight with a price target of $21, down from $34. While the ZEPHYR ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-downgraded-to-equal-weight-from-overweight-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-downgraded-to-equal-weight-from-overweight-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654058910","title":"MapLight Therapeutics is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2654058910","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654058910?lang=en_us&edition=fundamental","pubTime":"2026-07-28 18:28","pubTimestamp":1785234480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MPLT/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654071164","title":"U.S. Research Roundup- BioLife Solutions, Gossamer Bio, Intuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2654071164","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654071164?lang=en_us&edition=fundamental","pubTime":"2026-07-28 15:31","pubTimestamp":1785223918,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- BioLife Solutions, Gossamer Bio, IntuitJuly 28 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including BioL","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nL4N43U0K0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OWL","WDGF","CHMG","GTY","ENSG","MPLT","CUT","HCA","SRCE","CBOE","CDNS","HIG","NEE","BKR","GSHD","BLFS","HAPN","HRB","CLSK","AGYS","LMT","HUT","NVTS","CIFR","IP","IDU","HBT","HTH","LW","GDX","FRPT","LMTS","STCE","OTIS","BY","RNWZ","INTU","PINE","FMBH","FFIV","BWFG","LMTL","CHRW","DIPR","PPA","GOSS","BRBR","MSBI","NEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654078237","title":"Maplight Therapeutics Inc : Jefferies Cuts Target Price to $25 from $34","url":"https://stock-news.laohu8.com/highlight/detail?id=2654078237","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654078237?lang=en_us&edition=fundamental","pubTime":"2026-07-28 12:55","pubTimestamp":1785214549,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U09I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654204494","title":"Analysts Are Bullish on Top NA Stocks: Syensqo SA/NV (SHBBF), MapLight Therapeutics, Inc. (MPLT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654204494","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654204494?lang=en_us&edition=fundamental","pubTime":"2026-07-28 01:00","pubTimestamp":1785171618,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Syensqo SA/NV (SHBBF) and MapLight Therapeutics, Inc. (MPLT)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-syensqo-sa-nv-shbbf-maplight-therapeutics-inc-mplt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-syensqo-sa-nv-shbbf-maplight-therapeutics-inc-mplt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654801068","title":"MapLight's Schizophrenia Drug Fails Once-daily Test, Shares Plunge","url":"https://stock-news.laohu8.com/highlight/detail?id=2654801068","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654801068?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:27","pubTimestamp":1785155262,"startTime":"0","endTime":"0","summary":"MapLight's schizophrenia drug fails once-daily test, shares plungeJuly 27 (Reuters)-MapLight TherapeuticsMPLT.Osaid on Monday its schizophrenia drug failed to show statistically significant symptom im","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL4N43T0VE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","IHE","IE00BFXG1179.USD","IE00BJT1NW94.SGD","LU0306806265.USD","LU1261432733.SGD","LU2125154778.USD","FTXH","LU0306807586.USD","BK4588","IE00B2B36J28.USD","LU0225284248.USD","LU0321505868.SGD","LU1032466523.USD","LU1883839398.USD","LU1571399168.USD","LU0096364046.USD","LU1670711123.USD","LU0432979614.USD","BK4559","LU2133065610.SGD","MPLT","LU1291159041.SGD","LU1670711040.USD","LU1868836914.USD","LU1868837300.USD","IE0009355771.USD","LU1093756168.USD","IE00BFTCPJ56.SGD","LU1430594728.SGD","LU1323610961.USD","BMY","BK4534","LU1670710588.SGD","LU1074936037.SGD","LU1868837136.USD","LU2242646821.SGD","LU2360032135.SGD","LU0868494617.USD","LU1585245621.USD","LU1093756325.SGD","LU1718418525.SGD","LU1670710661.SGD","BK4007","LU1868836591.USD","LU1983299246.USD","LU2125154935.USD","LU0882574055.USD","LU0267386448.USD","LU0456855351.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654017731","title":"Maplight Therapeutics Shares Drop 55.7% Premarket After Co Announces Mid-Stage Trial Results for Schizophrenia Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2654017731","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654017731?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:12","pubTimestamp":1785154348,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL4N43T0X6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654012194","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2654012194","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654012194?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:39","pubTimestamp":1785152371,"startTime":"0","endTime":"0","summary":"STAK  shares were down 55% in Monday premarket trading after the earlier session's 602% rally.MapLight Therapeutics  stock was down 55% after the company said a phase 2 trial of ML-007C-MA in schizophrenia met its primary endpoint, demonstrating a significant reduction in severity of the condition versus placebo.Profusa  shares were down 18% after the company signed a non-binding term sheet to acquire a privately held commercial-stage diagnostics and toxicology testing company.Recon Technology  stock was down 15%, following the earlier session's 11.6% gain.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PFSA","BK4082","MPLT","BK4139","RCON","BK4179","STAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014028","title":"MapLight Therapeutics announces topline results from ZEPHYR trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014028","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014028?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:16","pubTimestamp":1785150965,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics (MPLT) announced topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA, an oral M1/M4 muscarinic agonist co-for...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-announces-topline-results-from-zephyr-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-announces-topline-results-from-zephyr-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0234570918.USD","LU1989772923.USD","LU1815333072.USD","SG9999011175.SGD","LU2360107671.USD","LU2506951875.HKD","IYG","LU1691799644.USD","SG9999000418.SGD","LU1974910355.USD","LU0353189680.USD","BK4227","LU1814569148.SGD","IPAY","LU0127658192.USD","LU0006306889.USD","LU1868837300.USD","STBQ","LU2403377893.USD","UYG","SG9999002232.USD","VFH","LU0345769631.USD","IE00BHPRN162.USD","LU0170899867.USD","MA","FDFF","LU0868494708.USD","LU2361044865.SGD","MPLT","LU2023250504.SGD","LU0642271901.SGD","LU0109391861.USD","LU0950375773.USD","LU2237957811.SGD","SGXZ51526630.SGD","XLF","LU2552382058.USD","LU1861217088.USD","LU1629891620.HKD","IE00BN29S564.USD","BK4534","IE000SO60NU8.SGD","LU0061474705.USD","LATR","LU0198837287.USD","LU1280957306.USD","FNCL","LU0912757837.SGD","LU2764262908.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014558","title":"MapLight Says Phase 2 Zephyr Trial Shows Ml-007c-ma Cuts PANSS Score in Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014558","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014558?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:02","pubTimestamp":1785150129,"startTime":"0","endTime":"0","summary":"MapLight says Phase 2 ZEPHYR trial shows ML-007C-MA cuts PANSS score in schizophreniaMapLight Therapeutics reported positive topline results from its Phase 2 ZEPHYR trial of ML-007C-MA in adults with ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL3f19z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","IE00B64PRP62.GBP","SG9999014039.USD","BCDF","LU2210149790.SGD","BK4585","IE00BN0W2V16.EUR","LU2210150020.SGD","MPLT","IE00BGHQF748.EUR","SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","LU2095319765.USD","IE00BKPKM429.USD","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654143780","title":"Maplight Therapeutics - to Proceed with Additional Registrational Trial and Engage FDA at End-of-Phase 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2654143780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654143780?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654142010","title":"Maplight Therapeutics Inc - 330/6 Mg Once-Daily (Qd) Dose Did not Achieve Statistical Significance on Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2654142010","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654142010?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014822","title":"Maplight Therapeutics Announces Positive Topline Results from Phase 2 Zephyr Trial of Ml-007C-Ma in Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014822","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014822?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014373","title":"Maplight Therapeutics - Ml-007C-Ma Well Tolerated with no Serious or Drug-Related Severe Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014373?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014340","title":"Maplight Therapeutics - 210/3 Mg Bid Dose Shows Significant Panss Improvement at Week 5 in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014340?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654601468","title":"MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2654601468","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654601468?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150000,"startTime":"0","endTime":"0","summary":"The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to place","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/27/3333379/0/en/MapLight-Therapeutics-Announces-Positive-Topline-Results-from-Phase-2-ZEPHYR-Trial-of-ML-007C-MA-in-Schizophrenia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1815333072.USD","LU1868836914.USD","BK4527","LU2360107671.USD","IYG","LU0107464264.USD","LU0061475181.USD","LU2077746001.SGD","LU0056508442.USD","IE00BKDWB100.SGD","LU0210533765.USD","IPAY","IE00B4JS1V06.HKD","VFH","STBQ","UYG","LU2092627202.USD","LU2506951958.HKD","LU1718418525.SGD","LU2168563687.JPY","LU2168564149.EUR","BID","MA","FDFF","LU2420271590.USD","LU0708995401.HKD","LU0823434583.USD","MPLT","IE000WAW04H5.SGD","LU0642271901.SGD","LU1983260115.SGD","ASD","LU0823421333.USD","LU0096362180.USD","LU1712237335.SGD","XLF","LU0557290698.USD","SG9999003800.SGD","LU0823421416.USD","LU1732800096.USD","LU1316542783.SGD","LU1861217088.USD","BK4139","LU1280957306.USD","LATR","BK4533","LU0823417653.USD","FNCL","BK4585","LU2092937148.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654098633","title":"MapLight Therapeutics (MPLT) Rally Puts Its CNS Story And Valuation In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2654098633","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654098633?lang=en_us&edition=fundamental","pubTime":"2026-07-27 08:26","pubTimestamp":1785111993,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics (MPLT) has drawn investor attention recently as its clinical-stage central nervous system pipeline, including candidates for schizophrenia, Alzheimer’s disease psychosis and Parkinson’s disease, trades around $36.56 with a market value near $1.66 billion.\nSee our latest analysis for MapLight Therapeutics.\nFor context, MapLight Therapeutics’ share price return has been strong over 2024, with a year to date gain of 118.01% and a 90 day share price return of 19.32%...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mplt/maplight-therapeutics/news/maplight-therapeutics-mplt-rally-puts-its-cns-story-and-valu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mplt/maplight-therapeutics/news/maplight-therapeutics-mplt-rally-puts-its-cns-story-and-valu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CNS","MPLT","BK4135","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653308984","title":"MapLight Therapeutics price target raised to $43 from $35 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2653308984","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653308984?lang=en_us&edition=fundamental","pubTime":"2026-07-24 18:50","pubTimestamp":1784890228,"startTime":"0","endTime":"0","summary":"Canaccord analyst Sumant Kulkarni raised the firm’s price target on MapLight Therapeutics (MPLT) to $43 from $35 and keeps a Buy rating on the shar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-price-target-raised-to-43-from-35-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-price-target-raised-to-43-from-35-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653701014","title":"U.S. Research Roundup-deckers Brands, Rollins, United Rentals","url":"https://stock-news.laohu8.com/highlight/detail?id=2653701014","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653701014?lang=en_us&edition=fundamental","pubTime":"2026-07-24 15:14","pubTimestamp":1784877253,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Deckers Brands, Rollins, United RentalsJuly 24 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Decker","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nL4N43Q0HS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THRM","R","CHPS","PKG","ACI","GPZ","FOA","BX","MOH","DFTX","EMET","AMP","KRMN","AMAT","PNFP","MEDP","FCNCA","MPLT","AMD","LMT","NSC","JUP.UK","TEK","FCX","INTC","NDAQ","CTSH","LRCX","BPOP","ALK","EW","DECK","DOMO","CMCSA","AMDS","DOW","HON","NIC","SAM","LOB","MBWM","SETM","ROL","AMUU","MISL","TINY","NVR","AAL","OBK","DOV"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":126,"code":"91000000","status":"200"}]}}